AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 151 min read$CLLS

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cellectis (NASDAQ:CL

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Original reporting
benzinga.com
Published Sep 15, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLLS
Bearish
medium confidence
Mentioned
$CLLS · $BSBR · $RBBN · $SRRK · $ASND
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CLLSBearishMed
01

Why it matters

The downgrades may lead to short-term price pressure on the affected stocks, though the overall market impact is limited.

02

Market read

Downgrades may trigger modest sell-offs in the listed stocks, with limited broader market effect.

03

What to watch

Potential upcoming earnings or sector catalysts could offset downgrade effects.

Relevance 6/10Novelty 6/10Timing: after Monday close

Background

Analyst rating changes are a routine part of market coverage, reflecting updated views on company prospects.

Company-level read

Ticker impact

$CLLSBearishMedium confidence
Context

Cellectis (NASDAQ:CLLS) was downgraded from Market Outperform to Market Perform.

Expected impact

Potential short-term decline

Evidence & confidence

Downgrade signals weaker outlook, likely prompting sell pressure.

$BSBRNeutralMedium confidence
Context

Banco Santander Brasil (NYSE:BSBR) was downgraded from Buy to Hold.

Expected impact

Flat to slight down

Evidence & confidence

Hold suggests no further upside, may temper buying.

$RBBNBearishMedium confidence
Context

Ribbon Communications (NASDAQ:RBBN) was downgraded from Buy to Neutral.

Expected impact

Possible modest decline

Evidence & confidence

Neutral stance often leads to reduced demand.

$SRRKNeutralMedium confidence
Context

Scholar Rock Holding (NASDAQ:SRRK) was downgraded from Overweight to Equal-Weight.

Expected impact

Flat to slight down

Evidence & confidence

Equal-Weight is a neutral stance, limiting upside.

$ASNDNeutralMedium confidence
Context

Ascendis Pharma (NASDAQ:ASND) was downgraded from Strong Buy to Outperform.

Expected impact

Flat to modest decline

Evidence & confidence

Reduced rating may temper enthusiasm.

Market effects

Sector

Analyst downgrades across diverse sectors may signal broader caution.

Regional

Primarily U.S. listed equities; limited regional effect.

Global

Low global impact beyond individual stocks.

Counterpoint

What could challenge this read

Some investors may view the downgrades as overreaction and look for buying opportunities.

Key entities

  • company
    Cellectis SA

    Biotech firm focused on gene editing.

  • company
    Banco Santander Brasil

    Brazilian banking subsidiary of Santander.

  • company
    Ribbon Communications

    Provider of communications software.

  • company
    Scholar Rock Holding Corp

    Life sciences contract research organization.

  • company
    Ascendis Pharma

    Biopharmaceutical company.

Read at source← All news

Related articles

SEP 17
$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

insidermonkey.com2 min
SEP 16
$CLLSHigh

Cellectis stock tumbles after Barclays double downgrade

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

investing.com2 min
SEP 15
$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

gurufocus.com2 min